About ESPERER
ESPERER is a Healthcare company based in Mumbai (India) founded in 2018 by Raktim Chattopadhyay. Oncology drugs are manufactured by Esperer in Mumbai, India. The company has 12 employees. Its chief executive, as recorded, is Raktim Chattopadhyay. Its Indian entity Esperer Bio-Research Private Limited reported revenue of ₹1.57 Cr. Its focus areas include Traditional Pharmaceuticals, Generics, Therapeutic Areas and Oncology.
Company details
Esperer was founded in 2018 and is headquartered in Mumbai, India. Oncology drugs are produced by the company within the pharmaceutical sector, with operations centered on bioresearch and development. Focus is placed on cancer-related treatments, supported by a team led by founder and CEO Raktim Chattopadhyay. Activities are conducted primarily in India, targeting the oncology market through manufacturing processes.
- Headquarters Mumbai, India
- Employees 12
- Founders Raktim Chattopadhyay
- SectorsHealthcare
- Website espererbioresearch.com
- Social LinkedIn
- Legal Name Esperer Bio-Research Private Limited
- Date of Incorporation 16 Aug, 2018
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹1.57 Cr
FY 2024 · -32% YoY
- Net Loss-₹2.44 Cr
FY 2024 · -155% margin
- EBITDA-₹1.99 Cr
FY 2024 · -126% margin
- Investors
- Employee Count12
Associated legal entities of ESPERER
ESPERER operates through Esperer Bio-Research Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Esperer Bio-Research Private Limited CIN U24304MH2018PTC312841 | Active | 16 Aug 2018 | Mumbai, Maharashtra | ₹1.6 Cr | 12 | 5 | View details |
Funding Insights of ESPERER
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of ESPERER with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | Seed | – | Zenfold | – |
1 investors in total: 1 institutional.
Investors in ESPERER
ESPERER has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Zenfold.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and venture building in high-growth areas, focusing on incubation and strategic partnerships. | 2017 | zenfold.in | Hyderabad, India |
Investor details for ESPERER
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Esperer Bio-Research Private Limited (ESPERER)
Esperer Bio-Research Private Limited is the primary company behind ESPERER. The board of Esperer Bio-Research Private Limited currently have 5 directors; the longest-serving is Sohilkumar Dahyabhai Tandel, appointed in 2018. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sohilkumar Dahyabhai Tandel DIN 08201474 | Director | 16 Aug 2018 | 8 yrs 2 mo | Esperer Bio-Research Private Limited |
| Raktim Chattopadhyay DIN 08201473 | Director | 16 Aug 2018 | 8 yrs 2 mo | Esperer Bio-Research Private Limited |
| Shubhankar Karmakar DIN 07695018 | Director | 01 Jan 2020 | 6 yrs 9 mo | Esperer Bio-Research Private Limited |
| Sudipta Chattopadhyay DIN 08721831 | Director | 12 Mar 2020 | 6 yrs 7 mo | Esperer Bio-Research Private Limited |
| Venkataktyayani Sushmitha Gorantla DIN 05184696 | Director | 23 Feb 2021 | 5 yrs 8 mo | Esperer Bio-Research Private Limited |
People of ESPERER
1 people are tracked at ESPERER (1 in leadership); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership |
Complete people profiles for ESPERER
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of ESPERER
Figures of Esperer Bio-Research Private Limited, the primary company behind ESPERER, for FY 2024. Revenue was ₹1.57 Cr (-32% year on year). Net loss was -₹2.44 Cr (-155% margin). EBITDA was -₹1.99 Cr (-126% margin). Revenue has grown at a compounded annual rate of +5% over three years and +3% over five years.
- ₹1.57 CrRevenue · FY 2024 · -32% YoY
- -₹2.44 CrNet loss · -155% margin
- -₹1.99 CrEBITDA · -126% margin
- ₹4.40 CrPaid-up capital
- 12Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +3%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Esperer Bio-Research Private Limited are on its company page.
Detailed financial statements for ESPERER
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ESPERER
2 dated milestones of ESPERER across 2 years, from founding to its latest funding, stage changes and deals.
- Founded ESPERER is founded.
- Funding First funding round.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as ESPERER (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Esperer
Complete news archive for ESPERER
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ESPERER
ESPERER was founded in 2018 and raised its 1st funding round 2 years after it was founded.
ESPERER is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Raktim Chattopadhyay is the CEO of ESPERER, as recorded in our data. They have also founded this company.
ESPERER has 12 employees.
The primary company behind ESPERER, Esperer Bio-Research Private Limited, reported revenue of ₹1.57 Cr for FY 2024, down 32% year on year.
Esperer was founded in 2018 and is headquartered in Mumbai, India. Oncology drugs are produced by the company within the pharmaceutical sector, with operations centered on bioresearch and development. Focus is placed on cancer-related treatments, supported by a team led by founder and CEO Raktim Chattopadhyay. Activities are conducted primarily in India, targeting the oncology market through manufacturing processes.
ESPERER has 1 investor. Key investors include Zenfold.
ESPERER operates through Esperer Bio-Research Private Limited.
The legal entities of ESPERER currently have 5 directors, including Venkataktyayani Sushmitha Gorantla, Sudipta Chattopadhyay, Shubhankar Karmakar and others.